
    
      A double-blind randomized controlled trial on the safety and immunogenicity of the
      recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases
      undergoing immunosuppressive or biologic/targeted DMARD therapies.

      Duration of study: 60 weeks
    
  